AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

Status:
RECRUITING

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.

PHASE2

Cytokinetics